How old is patient?
Anxiety, depression, asthenia. Psychogenic depressions, depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety & apathy. Menopausal depression.
Each tablet contains flupentixol (as dihydrochloride) 0.5 mg and melitracen (as hydrochloride) 10 mg.
Flupentixol/Melitracen also contains the following excipients: Tablet Core: Lactose monohydrate, potato starch, talc, gelatin, magnesium stearate. Coating: Gelatin, sucrose, sucrose powder, Flupentixol/Melitracen colour (erythrosine E127 and indigotine E132). Polishing Wax: Capol 1295 (a mixture of beeswax, white and carnauba wax).
Adults: Usually 2 tablets daily, morning and noon. In severe cases, the morning dose may be increased to 2 tablets. Maximum Dose: 4 tablets daily.
Elderly (>65 years): 1 tablet in the morning. In severe cases, 1 tablet in the morning and 1 at noon.
Maintenance Dose: Usually 1 tablet in the morning.
In cases of insomnia or severe restlessness, additional treatment with a sedative in the acute phase is recommended.
Reduced Renal and Liver Function: Flupentixol/Melitracen can be given in the recommended doses.
Administration: The tablets are swallowed with water.
Contraindicated Combinations: Monoamine oxidase inhibitors [nonselective as well as selective A (moclobemide) and B (selegiline)], risk of "serotonin syndrome".
Inadvisable Combinations: Sympathomimetic Agents: Melitracen may potentiate the cardiovascular effects of adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine and phenylpropanolamine (eg, as contained in local and general anaesthetics and nasal decongestants).
Adrenergic Neurone Blockers: Flupentixol/Melitracen may counteract the antihypertensive effects of guanethidine, betanidine, reserpine, clonidine and methyldopa. It is advisable to review all antihypertensive therapy during treatment with tricyclic antidepressants.
Anticholinergic Agents: Tricyclic antidepressants may potentiate the effects of these drugs on the eye, central nervous system (CNS), bowel and bladder; concomitant use of these should be avoided due to an increased risk of paralytic ileus, hyperpyrexia.
Drugs Which May Increase the QT Interval: Increases in the QT interval related to antipsychotic treatment may be exacerbated by the co-administration of other drugs known to significantly increase the QT interval. Co-administration of such drugs should be avoided. Relevant classes include: Class Ia and III antiarrhythmics (eg, quinidine, amiodarone, sotalol, dofetilide); some antipsychotics (eg, thioridazine); some macrolides (eg, erythromycin); some antihistamine (eg, terfenadine, astemizole); some quinolone antibiotics (eg, gatifloxacin, moxifloxacin).
The list mentioned is not exhaustive and other individual drugs known to significantly increase QT interval (eg, cisapride, lithium) should be avoided.
Drugs known to cause electrolyte disturbances eg, thiazide diuretica (hypokalaemia) and drugs known to increase the plasma concentration of flupentixol should also be used with caution as they may increase the risk of QT prolongation and malignant arrhythmias.
Combinations Requiring Precautions for Use: Central Nervous System Depressants: Flupentixol/Melitracen may enhance the effects of alcohol, barbiturates and other CNS depressants.
Lithium: Concomitant use of Flupentixol/Melitracen and lithium increases the risk of neurotoxicity.
Levodopa: Flupentixol/Melitracen may reduce the effect of levodopa and increase the risk of cardiac side effects.
Incompatibilities: Not applicable.
Flupentixol/Melitracen side effects
Dryness of the mouth, dizziness, tremor, nervousness, blurred vision and insomnia are the most frequent adverse effects and occur commonly.
In the listing as follows, the following convention is used: MedDRA system organ class or preferred term.
Frequencies are defined as: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); or not known (cannot be estimated from available data).
Post-Marketing: Isolated cases of cholestatic hepatitis have been reported.
Reporting of Suspected Adverse Reactions: Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.
Hypersensitivity to flupentixol or melitracen or to any of the excipients of Flupentixol/Melitracen.
Circulatory collapse, depressed level of consciousness due to any cause (eg, intoxication with alcohol, barbiturates or opiates), coma, blood disorders, phaeochromocytoma.
Recent myocardial infarction. Any degree of atrioventricular block or disorders of cardiac rhythm and coronary artery insufficiency.
Concomitant treatment with monoamine oxidase inhibitors (MAOIs) is contraindicated. Simultaneous administration of melitracen and MAOIs may cause serotonin syndrome (a combination of symptoms, possibly including agitation, confusion, tremor, myoclonus and hyperthermia).
As with other tricyclic antidepressants, melitracen should not be given to patients receiving MAOIs. Treatment with Flupentixol/Melitracen may be instituted 14 days after discontinuation of nonselective MAOIs and minimum 1 day after discontinuation of moclobemide and selegiline. Treatment with MAOIs may be introduced 14 days after discontinuation of Flupentixol/Melitracen.
Active ingredient matches for Flupentixol/Melitracen:
List of Flupentixol/Melitracen substitutes (brand and generic names)
|Sort by popularity|
|Unit description / dosage (Manufacturer)||Price, USD|
|Flupen-M Flupentixol 0.5mg, melitracen10mg TAB / 10||$ 0.71|
|Fluxit 20 mg Capsule (Alpic Remedies Ltd.)||$ 0.03|
|Forcalm flupentixol 10mg, melitracen0.5mg TAB / 10 (Unichem Laboratories Ltd.)||$ 0.71|
|10's (Unichem Laboratories Ltd.)||$ 0.71|
|Forcalm 10+0.5 Tablet (Unichem Laboratories Ltd.)||$ 0.07|
|FORCALM 10MG/0.5MG TABLET 1 strip / 10 tablets each (Unichem Laboratories Ltd.)||$ 0.78|
|Franxit Flupenthixol 0.5 mg, Melitracen 10 mg. TAB / 10 (Intas Pharmaceuticals Ltd.)||$ 0.68|
|10's (Intas Pharmaceuticals Ltd.)||$ 0.68|
|Franxit 10+0.5 Tablet (Intas Pharmaceuticals Ltd.)||$ 0.08|
|FRANXIT 0.5 MG/10 MG TABLET 1 strip / 10 tablets each (Intas Pharmaceuticals Ltd.)||$ 0.86|
|Franxit 0.5 mg/10 mg Tablet (Intas Pharmaceuticals Ltd.)||$ 0.09|
|Fycida-M Flupenthixol 0.5 mg, Melitracen 10 mg. TAB / 100|
|Melicen -FP flupentixol 0.5mg, melitracen10mg FC-TAB / 100||$ 7.94|
|Melixol (Bangladesh, Taiwan)|
|MELIXOL 10MG/0.5MG TABLET 1 strip / 10 tablets each (Reliance Formulation Pvt Ltd)||$ 0.81|
|Melixol 10 mg/0.5 mg Tablet (Reliance Formulation Pvt Ltd)||$ 0.08|
|Meliyos Flupentixol 0.5 mg, Melitracenhydrochloride 10 mg. TAB / 10||$ 0.79|
|Melthix flupentixol 0.5mg, melitracen10mg SC-TAB / 10||$ 0.76|
|MELTHIX 0.5MG/10MG TABLET 1 strip / 10 tablets each (Molekule India Pvt Ltd)||$ 0.91|
|Melthix flupentixol 0.5mg, melitracen10mg SC-TAB / 10||$ 0.76|
|Melxol Flupentixol 0.5 mg, Melitracenhydrochloride 10 mg. TAB / 10||$ 0.94|
|Modaxit Flupentixol 0.5 mg, Melitracen10 mg. TAB / 10||$ 0.87|
|Moody Flupentixol dihydrochloride0.5 mg, Melitracenhydrochloride 10 mg. TAB / 100||$ 7.62|
|MOODY 0.5MG/10MG TABLET 1 strip / 10 tablets each (Cure Quick Pharmaceuticals)||$ 0.76|
|Moody 0.5 mg/10 mg Tablet (Cure Quick Pharmaceuticals)||$ 0.08|
|Novoxit Flupentixol 0.5 mg, Melitracen10 mg. TAB / 100 (Novogen Captab Biotec (Novo Nordisk Pharma India Ltd))||$ 8.33|
- PubChem. "Flupentixol". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Flupentixol". http://www.drugbank.ca/drugs/DB00875 (accessed September 17, 2018).
- MeSH. "Antipsychotic Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Flupentixol/Melitracen are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Flupentixol/Melitracen. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
2 consumers reported age
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology